Hart D - Search Results

1

Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J. Joshua D, et al. Among authors: hart d. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi: 10.1016/j.clml.2016.08.003. Epub 2016 Aug 10. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27601001 Review.

2

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D. Brown R, et al. Among authors: hart d. Br J Haematol. 2004 Jun;125(6):743-8. doi: 10.1111/j.1365-2141.2004.04984.x. Br J Haematol. 2004. PMID: 15180863 Free article.

3

CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis.

Brown R, Kabani K, Favaloro J, Yang S, Ho PJ, Gibson J, Fromm P, Suen H, Woodland N, Nassif N, Hart D, Joshua D. Brown R, et al. Among authors: hart d. Blood. 2012 Sep 6;120(10):2055-63. doi: 10.1182/blood-2012-03-416792. Epub 2012 Jun 15. Blood. 2012. PMID: 22705596 Free article.

4

Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state.

Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, Joshua D. Favaloro J, et al. Among authors: hart d. Leuk Lymphoma. 2014 May;55(5):1090-8. doi: 10.3109/10428194.2013.825905. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23865833

5

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.

Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, Nassif N, Hart D, Fromm P, Weatherburn C, Gibson J, Ho PJ, Joshua D. Favaloro J, et al. Among authors: hart d. Leuk Lymphoma. 2014 Dec;55(12):2893-900. doi: 10.3109/10428194.2014.904511. Epub 2014 May 12. Leuk Lymphoma. 2014. PMID: 24625328

6

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J. McAuliffe S, et al. Among authors: hart d. Leuk Lymphoma. 2015;56(9):2714-6. doi: 10.3109/10428194.2014.1003061. Epub 2015 Feb 17. Leuk Lymphoma. 2015. PMID: 25651422 No abstract available.

7

DC in multiple myeloma immunotherapy.

Turtle CJ, Brown RD, Joshua DE, Hart DN. Turtle CJ, et al. Among authors: hart dn. Cytotherapy. 2004;6(2):128-37. doi: 10.1080/14653240410005357. Cytotherapy. 2004. PMID: 15203989 Review.

8

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. Seldon TA, et al. Among authors: hart dn. Leukemia. 2016 Mar;30(3):692-700. doi: 10.1038/leu.2015.231. Epub 2015 Aug 19. Leukemia. 2016. PMID: 26286117

9

Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma.

Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, Turtle CJ, Prue RL, Hart DN. Vari F, et al. Among authors: hart dn. Br J Haematol. 2008 Nov;143(3):374-7. doi: 10.1111/j.1365-2141.2008.07346.x. Epub 2008 Aug 20. Br J Haematol. 2008. PMID: 18729856 Free article.

10

Dendritic cell biology evolves into clinical application.

Hart DN. Hart DN. Lancet. 2005 Jan 8-14;365(9454):102-4. doi: 10.1016/S0140-6736(05)17717-4. Lancet. 2005. PMID: 15639277 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,108 results

Search Page